Osteoporosis: Diagnosis, prevention, and treatment of established disease

Bulletin on the Rheumatic Diseases

Volumn 48, Issue 6, 1999, Pages 1-4

  Dunlop, Miranda B V ^a   Lane, Nancy E ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

BONE DENSITY; BONE GROWTH; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; EXERCISE; FRACTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK FACTOR;

AGE FACTORS; AGED; ALENDRONATE; CALCITONIN; CALCIUM CHANNEL BLOCKERS; CALCIUM, DIETARY; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; ESTROGENS; ETIDRONIC ACID; EXERCISE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RALOXIFENE; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VITAMIN D;

EID: 0032887658     PISSN: 00075248     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Consensus Development Conference on Osteoporosis. 1993 Apr 1-2; Hong Kong; Am J Med 1994; 95(5A)1S-78S.
2. Nevitt MC. Epidemiology of osteoporosis. Rheum Dis Clin North Am 1994;20:535-59.
3. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med 1992;327: 620-27.
4. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs, BL. How many women have osteoporosis? J Bone Miner Res 1992;7:1005-10.
5. Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:24-35.
6. Teegarden D, Proulx WR, Martin BR, et al. Peak bone mass in young women. J Bone Miner Res 1995;10:(5)711-715.
7. Lane N, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinology and Metabolism Clin North Am 1998;27:465-85.
8. Nevitt MC. Epidemiology of osteoporosis. Rheum Dis Clin North Am 1994;20:535-59.
9. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women: the study of osteoporotic fractures. N Engl J Med 1995;332:767-73.
10. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-40.
11. Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227-33.
12. Reid IR, Ames RW, Evans MC, et al. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993;328: 460.
13. Cauley JA, Seeley DG, Ensrud K, et al. Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995;5:23-9.
14. Ensrud K, Black D, Recker S, et al. The effect of 2 and 3 years of raloxifene on vertebral and nonvertebral fractures in postmenopausal women with osteoporosis [abstract]. Bone 1998;23 Suppl 5:S174.
15. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal woman. JAMA 1999;281:2189-97.
16. Liberman UA, Weiss SR, Breoll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
17. Silverman SL, Chasnut C, Andriano K, et al. Salmon calcitonin nasal spray reduces risk of vertebral fractures in established osteoporosis and has continuous efficacy with prolonged treatment: accrued 5-year worldwide data of the PROOF study [abstract]. Bone 1998;23 Suppl 5:S174.